Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 2/20 | 0.44 |
| ▸ | AXL | P30530 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3831757 | 0.91 | MET (0.39) | LMNAKDM4EMETAXLRXFP1 | |
| SCHEMBL14975601 | 0.86 | MET (0.43) | LMNAKDM4EMETAXLRXFP1 | |
| SCHEMBL201513 | 0.85 | NOTUM (0.45) | LMNAKDM4EMETAXLKMT2A | |
| SCHEMBL22249789 | 0.82 | MEN1 (0.49) | LMNAKDM4EMETAXLRXFP1 | |
| SCHEMBL680256 | 0.81 | LMNA (0.44) | LMNAKDM4EMETRXFP1TP53 | |
| SCHEMBL22923879 | 0.79 | LMNA (0.49) | LMNAKDM4ERXFP1TP53KMT2A | |
| SCHEMBL15506084 | 0.78 | CA12 (0.47) | LMNAKDM4EMETAXLRXFP1 | |
| SCHEMBL12503583 | 0.78 | GRM1 (0.47) | LMNAKDM4EMETAXLRXFP1 | |
| SCHEMBL721541 | 0.75 | MET (0.50) | LMNAKDM4EMETAXLRXFP1 | |
| SCHEMBL16863427 | 0.75 | MET (0.49) | LMNAKDM4EMETAXLRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2609100-B1 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-06-24 | — | — | EP | claimed |
| EP-2609100-A2 | FUROPYRIDINE DERIVATIVES | Merck Patent GmbH (DE) | 2013-07-03 | — | — | EP | claimed |
| WO-2012025187-A2 | FUROPYRIDINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-03-01 | — | — | WO | claimed |
| US-12595273-B2 | Phosphonate conjugates and uses thereof | TRANSLATIONAL GENOMICS RES INST (US) | 2026-04-07 | — | — | US | disclosed |
| US-20230339889-A1 | DERIVATIVES OF 2-OXO-N-(4-(PYRIMIDIN-4-YLOXY/THIO)PHENYL)-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE FOR USE AS PROTEIN KINASE INHIBITORS FOR THERAPY | AUCENTRA THERAPEUTICS PTY LTD (AU) | 2023-10-26 | — | — | US | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156864-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-24 | — | — | WO | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | CMG PHARMACEUTICAL CO., LTD. (KR) | 2023-08-17 | — | — | US | disclosed |
| EP-4178953-A1 | DERIVATIVES OF 2-OXO-N-(4-(PYRIMIDIN-4-YLOXY/THIO)PHENYL)-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE FOR USE AS PROTEIN KINASE INHIBITORS FOR THERAPY | Aucentra Therapeutics Pty Ltd (AU) | 2023-05-17 | — | — | EP | disclosed |
| CN-101535264-A | pyridone compound | BRISTOL MYERS SQUIBB CO (US) | 2009-09-16 | — | — | CN | disclosed |
| EP-2089364-A1 | PYRIDINONE COMPOUNDS | Brystol-Myers Squibb Company (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009094427-A1 | 4-PYRIDINONE COMPOUNDS AND THEIR USE FOR CANCER | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-30 | — | — | WO | disclosed |
| WO-2008058229-A1 | PYRIDINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
| WO-2008058229-A1 | PYRIDINONE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257364-A1 | PYRIDAZINONE-BASED COMPOUNDS AS AXL, C-MET, AND MER INHIBITORS AND METHODS OF USE THEREOF | MERTK, MET, AXL | LMNA 3490/4885KDM4E 1456/4885MET 2/4885 |
| US-20230339889-A1 | DERIVATIVES OF 2-OXO-N-(4-(PYRIMIDIN-4-YLOXY/THIO)PHENYL)-1,2-DIHYDROPYRIDINE-3-CARBOXAMIDE FOR USE AS PROTEIN KINASE INHIBITORS FOR THERAPY | TYRO3, MERTK, ERBB2 | LMNA 3677/4885KDM4E 1071/4885MET 6/4885 |
| US-12595273-B2 | Phosphonate conjugates and uses thereof | RET, PTK2, ERBB2 | LMNA 3967/4885KDM4E 3638/4885MET 46/4885 |
| US-20080114033-A1 | N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide; Met kinase inhibitor; hypatocyte growth factor antagonist; anticarcinogenic agent | MET, HGF, DCK | LMNA 2395/4885KDM4E 205/4885MET 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.